Structural determinants of the partial agonist-inverse agonist properties of 6′-azidohex-2′-yne-Δ8-tetrahydrocannabinol at cannabinoid receptors

被引:50
作者
Ross, RA
Gibson, TM
Stevenson, LA
Saha, B
Crocker, P
Razdan, RK
Pertwee, RG [1 ]
机构
[1] Univ Aberdeen, Inst Med Sci, Dept Biomed Sci, Aberdeen AB25 2ZD, Scotland
[2] Organix Inc, Woburn, MA 01801 USA
基金
英国惠康基金;
关键词
cannabinoids; cannabinoid CB1 receptors; cannabinoid CB2 receptors; inverse agonism; 6 '-azidohex-2 '-yne-Delta(8-)tetrahydrocannabinol; O-1184; mouse vas deferens;
D O I
10.1038/sj.bjp.0702836
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 We have extended previous investigations of four analogues of Delta(8)-tetrahydrocannabinol (Delta(8)-THC): 6'-azidohex-2'-yne-Delta(8)-THC (O-1184), 6'-azidohex-cis-2'-ene-Delta(8)-THC (O-1238) and octyl-2'-yne-Delta(8)-THC (O-584) and its I-deoxy-analogue (O-1315). 2 O-1184, O-1238 and O-584 displaced [H-3]-CP55940 from specific binding sites on Chinese hamster ovary (CHO) cell membranes expressing CB1 or CB2 cannabinoid receptors, with pK(i) values of 8.28 to 8.45 (CBi) and 8.03 to 8.13 (CB2). The pK(i) values of O-1315 were significantly less, 7.63 (CB1) and 7.01 (CB2). 3 All the analogues inhibited forskolin-stimulated cyclic AMP production by CB1-transfected CHO cells(pEC(50) = 9.16 to 9.72). Only O-1238 behaved as a full agonist in this cell line. 4 In mouse vasa deferentia, O-1238 inhibited electrically-evoked contractions (pEC(50) = 10.18 and E-max = 70.5%). Corresponding values for O-1184 were 9.08 and 21.1% respectively. At 1 nM, O-1184 produced surmountable antagonism of the cannabinoid receptor agonist, CP55940. However, at 0.1 nM, O-1184 did not attenuate CP55940-induced inhibition of cyclic AMP production by CB(1-)transfected CHO cells. 5 In CB2-transfected CHO cells, cyclic AMP production was inhibited by CP55940 (pEC(50) = 8.59), enhanced by O-1184 and O-584 (pEC(50) = 8.20 and 6.86 respectively) and not significantly affected by O-1238 or O-1315. 6 At 100 nM, O-1184 and O-1238 produced surmountable antagonism of CP55940 in CB2 cells, decreasing the pEC(50) of CP55940 from 8.61 to 7.42 (O-1184) or from 8.54 to 7.44 (O-1238). 7 These data support the hypothesis that increasing the degree of unsaturation of the aliphatic side-chain of Delta(8)-THC analogues has little effect on CB1 or CB2 receptor affinity but can reduce CB1 receptor efficacy and reverse the direction of responses elicited at CB2 receptors.
引用
收藏
页码:735 / 743
页数:9
相关论文
共 20 条
[1]   A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1 - Evidence for a new model of receptor/ligand interactions [J].
Bouaboula, M ;
Perrachon, S ;
Milligan, L ;
Canat, X ;
RinaldiCarmona, M ;
Portier, M ;
Barth, F ;
Calandra, B ;
Pecceu, F ;
Lupker, J ;
Maffrand, JP ;
LeFur, G ;
Casellas, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (35) :22330-22339
[2]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[3]  
Colquhoun D., 1971, LECT BIOSTATISTICS
[4]  
COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218
[5]  
Green A., 1999, British Journal of Pharmacology, V126, p112P
[6]   Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals [J].
Griffin, G ;
Fernando, SR ;
Ross, RA ;
McKay, NG ;
Ashford, MLJ ;
Shire, D ;
Huffman, JW ;
Yu, S ;
Lainton, JAH ;
Pertwee, RG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 339 (01) :53-61
[7]   An investigation into the structural determinants of cannabinoid receptor ligand efficacy [J].
Griffin, G ;
Wray, EJ ;
Rorrer, WK ;
Crocker, PJ ;
Ryan, WJ ;
Saha, B ;
Razdan, RK ;
Martin, BR ;
Abood, ME .
BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (07) :1575-1584
[8]   Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor [J].
Huffman, JW ;
Yu, S ;
Showalter, V ;
Abood, ME ;
Wiley, JL ;
Compton, DR ;
Martin, BR ;
Bramblett, RD ;
Reggio, PH .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) :3875-3877
[9]  
HUFFMAN JW, 1998, S CANN BURL VERM INT, P10
[10]  
Kenakin T., 1993, PHARM ANAL DRUG RECE